Literature DB >> 16234465

Choroidal neovascularisation in pathological myopia: an update in management.

W-M Chan1, M Ohji, T Y Y Lai, D T L Liu, Y Tano, D S C Lam.   

Abstract

Choroidal neovascularisation (CNV) secondary to pathological myopia is an important cause of significant visual impairment in young and middle aged adults globally and is particularly prevalent in Asian populations. In the past few years, there have been rapid advancements in the different treatments for myopic CNV. The purpose of this perspective is to give an overview of the natural history of myopic CNV and the various treatment options including laser photocoagulation, photodynamic therapy, sub-macular surgery, and macular translocation surgery. Future directions in the management of myopic CNV are also discussed.

Entities:  

Mesh:

Year:  2005        PMID: 16234465      PMCID: PMC1772951          DOI: 10.1136/bjo.2005.074716

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  89 in total

1.  Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes.

Authors:  Salomon Y Cohen; Alexandra Bulik; Lise Dubois; Gabriel Quentel
Journal:  Am J Ophthalmol       Date:  2003-08       Impact factor: 5.258

2.  Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery.

Authors:  W-M Chan; D S C Lam; D T L Liu; T-H Wong; K S C Yuen
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

3.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

4.  Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia.

Authors:  K Ohno-Matsui; T Yoshida; S Futagami; K Yasuzumi; N Shimada; A Kojima; T Tokoro; M Mochizuki
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

5.  A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy.

Authors:  M N Moschos; D Panayotidis; M M Moschos; Chr Bouros; P G Theodossiadis; G P Theodossiadis
Journal:  Eur J Ophthalmol       Date:  2003-06       Impact factor: 2.597

6.  Myopic choroidal neovascularization: a 10-year follow-up.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Kenjiro Yasuzumi; Ariko Kojima; Noriaki Shimada; Soh Futagami; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

7.  Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

8.  Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment.

Authors:  Rogério A Costa; Daniela Calucci; Luiz F Teixeira; Jose A Cardillo; Pedro P Bonomo
Journal:  Am J Ophthalmol       Date:  2003-06       Impact factor: 5.258

9.  Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes.

Authors:  J M Ruiz-Moreno; J A Montero
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

10.  Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia.

Authors:  Francesco Bandello; Paolo Lanzetta; Maurizio Battaglia Parodi; Derri Roman-Pognuz; Sandro Saviano; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-18       Impact factor: 3.117

View more
  27 in total

1.  Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration.

Authors:  K Takeuchi; S Kachi; E Iwata; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

2.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

3.  Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Authors:  P J Rosenfeld
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

4.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

5.  [Unusual myopic fundus alteration].

Authors:  C Münzenberg; F Paulsen; T Kalinski; A Dmitriew; G I W Duncker; S Sel
Journal:  Ophthalmologe       Date:  2009-07       Impact factor: 1.059

Review 6.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

7.  Association analysis of retinoic acid receptor beta (RARbeta) gene with high myopia in Chinese subjects.

Authors:  Yang Ding; Xiaoyan Chen; Dongsheng Yan; Anquan Xue; Fan Lu; Jia Qu; Xiangtian Zhou
Journal:  Mol Vis       Date:  2010-05-13       Impact factor: 2.367

8.  Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.

Authors:  A Tufail; P J Patel; S Sivaprasad; W Amoaku; A C Browning; M Cole; R Gale; S George; A J Lotery; M Majid; M McKibbin; G Menon; Y Yang; C Andrews; C Brittain; A Osborne
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

9.  Changes in choroidal thickness and optical axial length accompanying intraocular pressure increase.

Authors:  Masayuki Hata; Fumitaka Hirose; Akio Oishi; Yasuhiko Hirami; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2012-08-11       Impact factor: 2.447

Review 10.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.